Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
660 participants
OBSERVATIONAL
2012-02-29
2015-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
NCT02447328
Faslodex Observations During Regular Use by Advanced Mammacarcinoma Patients
NCT00241462
Faslodex International Observational Non-Interventional Study in Advanced Breast Cancer (BC)
NCT00880711
Retrospective Study Assessment Treatment Response Faslodex®( 500 mg)
NCT01509625
Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
NCT00093002
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Faslodex
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shigeru Yoshida
Role: STUDY_DIRECTOR
AstraZeneca KK
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Aichi, , Japan
Research Site
Akita, , Japan
Research Site
Aomori, , Japan
Research Site
Chiba, , Japan
Research Site
Fukui, , Japan
Research Site
Fukuoka, , Japan
Research Site
Fukushima, , Japan
Research Site
Gifu, , Japan
Research Site
Gunma, , Japan
Research Site
Hiroshima, , Japan
Research Site
Hokkaido, , Japan
Research Site
Hyōgo, , Japan
Research Site
Ibaraki, , Japan
Research Site
Ishikawa, , Japan
Research Site
Kagawa, , Japan
Research Site
Kagoshima, , Japan
Research Site
Kanagawa, , Japan
Research Site
Kochi, , Japan
Research Site
Kumamoto, , Japan
Research Site
Kyoto, , Japan
Research Site
Miyagi, , Japan
Research Site
Miyazaki, , Japan
Research Site
Nagano, , Japan
Research Site
Nagasaki, , Japan
Research Site
Nara, , Japan
Research Site
Niigata, , Japan
Research Site
Okayama, , Japan
Research Site
Okinawa, , Japan
Research Site
Osaka, , Japan
Research Site
Ōita, , Japan
Research Site
Saga, , Japan
Research Site
Saitama, , Japan
Research Site
Shiga, , Japan
Research Site
Shizuoka, , Japan
Research Site
Tochigi, , Japan
Research Site
Tokushima, , Japan
Research Site
Tokyo, , Japan
Research Site
Tottori, , Japan
Research Site
Toyama, , Japan
Research Site
Wakayama, , Japan
Research Site
Yamagata, , Japan
Research Site
Yamaguchi, , Japan
Research Site
Yamanashi, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
CSR\_Synopsis\_D6997C00008
D6997C00008Fulvestrant\_Specific\_Clinical\_Experience\_Investigation\_Protocol\_redacted\_23February2016
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D6997C00008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.